Alzamend Neuro (ALZN) Stock Price, News & Analysis

Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.66 to $1.72
• 50-Day Range: $1.68 to $5.85
• 52-Week Range: $1.60 to $38.97
• Volume: 143,493 shs
• Average Volume: 576,210 shs
• Market Capitalization: $13.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Alzamend Neuro Stock Analysis - MarketRank™

Alzamend Neuro scored higher than 5% of companies evaluated by MarketBeat, and ranked 933rd out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Alzamend Neuro.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Alzamend Neuro is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alzamend Neuro is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.65% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently increased by 162.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alzamend Neuro does not currently pay a dividend.

Dividend Growth

Alzamend Neuro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.65% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently increased by 162.16%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 6 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Alzamend Neuro insiders have bought more of their company's stock than they have sold. Specifically, they have bought $300.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.55% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALZN Stock Analysis - Frequently Asked Questions

How have ALZN shares performed this year?

Alzamend Neuro's stock was trading at $8.90 at the start of the year. Since then, ALZN shares have decreased by 81.0% and is now trading at $1.69.
View the best growth stocks for 2024 here.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its quarterly earnings results on Wednesday, September, 11th. The company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($2.38) by $1.13.

When did Alzamend Neuro's stock split?

Alzamend Neuro's stock reverse split on the morning of Tuesday, July 16th 2024. The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.

Who are Alzamend Neuro's major shareholders?

Alzamend Neuro's top institutional shareholders include Concourse Financial Group Securities Inc.. Insiders that own company stock include Milton C Ault III, Milton C Ault III, Milton C Ault III, David J Katzoff, Mark Gustafson, Stephan Jackman and Lynne Fahey Mcgrath.
View institutional ownership trends.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 9/11/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 12/20/2024
• Fiscal Year End: 4/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALZN
• CUSIP: N/A
• CIK: 1677077
• Web: www.alzamend.com
• Phone: 844-722-6303
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,950,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -197.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.52) per share
• Price / Book: -0.48

Miscellaneous

• Outstanding Shares: 7,982,000
• Free Float: 7,140,000
• Market Cap: $13.41 million
• Optionable: Optionable
• Beta: -0.01